The global Viral Vector Development Market is expected to enjoy a valuation of USD 730.7 Million by the end of the year 2023, and further expand at a CAGR of 18.7% to reach a valuation of USD 4.1 Billion by the year 2033.
According to the recent study by Future Market Insights, adeno-associated viral vectors (AAV) are leading the market with an expected share of about 37.0% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 624.7 Million |
| Market Value 2023 | USD 730.7 Million |
| Market Value 2033 | USD 4.1 Billion |
| CAGR 2023 to 2033 | 18.7% |
| Market Share of Top 5 Countries | 57.5% |
| Key Market Players List | Thermo Fisher Scientific Inc; Charles River (Cobra Biologics); NOVASEP; uniQure N.V; Waisman Biomanufacturing; Creative Biogene; GenScript Biotech Corporation; Novartis AG ; Merck KGaA; Takara Bio, Inc.; FUJIFILM Diosynth Biotechnologies; LONZA; Danaher Corp. (Aldevron); Sirion Biotech GmbH; and AGC Biologics |
Since viral vectors are created utilising animal cell cultures, and in some cases insect cell cultures, they are essentially made from viruses which naturally infect human or other mammalian cells.
The last ten years have seen a tremendous advancement in manufacturing techniques for the development of clinical grade viral vectors. This is crucial for gene therapy methods implemented to the treatment of congenital or acquired disorders.
AAV and lentiviral vectors are currently being used more frequently for in vivo and ex vivo gene delivery, respectively.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for viral vector development was approximately 35.5% of the overall ~USD 30.86 Million of the global cancer gene therapy market in 2022.
The sale of viral vector development expanded at a CAGR of 14.5% from 2017 to 2022.
Traditional medicine researchers and the medical world have long believed that hereditary disorders are incurable. Genetic therapy, on the other hand, heralded a new era in medicine by offering the chance to fix the damaged genes that cause certain inherited illnesses.
Adeno-associated virus, often known as AAV, is frequently utilised as a carrier in the gene therapy procedure. The products made with viral vectors are proving to be suitable for the market because gene therapy has numerous potential applications in the medical sciences. Many biopharmaceutical companies are engaged in manufacturing and supply, which could be aimed at balancing the demand-supply ratio.
Despite the unexpected disruption of the world economy for all products during the pandemic years that followed the outbreak of COVID-19 infections, it offered tremendous chances for the viral vector CDMO business to expand globally.
The search for a therapeutic approach and a vaccine to prevent the causal pathogen's rapid spread involved numerous research centres and private biopharmaceutical businesses.
It was necessary to cultivate a novel coronavirus in order to build any kind of countermeasure, which raised the need for viral vector products. Private manufacturing firms and public institutions developing viral vectors drove the production and supply of all varieties of viral vectors, including recombinant adenoviral vectors.
The AAV-based vaccine for COVID-19 infection prevention is currently been developed by a number of businesses and state organisations. The global viral vector market will be driven by the COVID-19, which is the subject of extensive research to produce a more effective vaccination for the upcoming years.
Thus, owing to the aforementioned factors, the global viral vector development market is expected to grow at a CAGR of 18.7% during the forecast period between 2023 and 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan - Jun (H1), 2021 (A) | 13.21% |
| Jul - Dec (H2), 2021 (A) | 16.95% |
| Jan - Jun (H1),2022 Projected (P) | 13.65% |
| Jan - Jun (H1),2022 Outlook (O) | 14.28% |
| Jul - Dec (H2), 2022 Outlook (O) | 17.66% |
| Jul - Dec (H2), 2022 Projected (P) | 16.92% |
| Jan - Jun (H1), 2023 Projected (P) | 15.08% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 63↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 107↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 74↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 71↑ |
Gene therapy is necessary to repair suppressed and malfunctioning genes in human cells or tissues and return the abnormality to normal levels. Viral vector technology is used to cultivate the gene, and this business has grown significantly for many private players.
For the most part, two different types of techniques are used to use viral vectors in the gene therapy-induced healing process.
When it comes to 2D planer technologies, scaling out of adherent cell systems is a common strategy that has been applied up until the point of market analysis. The production of suspension AAV by diverse segments will, therefore, rely increasingly on 3D suspension cell cultures or bioreactors in the upcoming period.
The synthesis of viral vectors using cell culture technology has been successfully modified to satisfy the demands of both early and advanced clinical trial phases. Scale-up, however, may still be constrained depending on the vector type and the cell culture production platforms chosen.
Presently, great progress is being made in the generation of cell lines that can create inducible or constitutively expressed lentiviral vectors that grow in suspension. Recently, the first batch of lentiviral vectors generated by reliable producer cell lines was utilised in a clinical trial setting.
With extensive safety and efficacy data gathered from various clinical trials, it is evident that gene therapy is making great progress. These factors are set to promote the expansion of the global market, over the forecast period.
Principal Consultant
The deployment of exceedingly complex procedures was brought about by the need for clinical-grade, thoroughly polished final products. For the initial set of production units, such advanced technological techniques require a significant investment from the viral vector firms.
The primary barrier to the rapid development of viral vectors for varied purposes remains the strict government requirements for sanctioning any new development related to the healthcare sector.
The global viral vector development market's expansion is undoubtedly constrained by the lack of enough good laboratories for the testing and approval of essential raw materials.
Due to its superior safety profile and effective transduction to a variety of target tissues, adeno-associated virus (AAV) has become a major platform for the delivery of genes for the treatment of many disorders.
Viral vectors are less effective than recombinant protein treatments in large-scale production and long-term preservation, which results in lower yields, a modest level of purity, and a shorter shelf life.
The cost-effective manufacture of viral vectors remains a challenge despite notable clinical and commercial accomplishments, primarily because it is unclear how different methods affect the quality and shelf-life of AAV products.
This is because AAV gene therapy's clinical progress has outpaced its CMC, manufacturing, and formulation development. These factors are expected to restrain the market expansion over the forecast period.
| Country | The USA |
|---|---|
| Market Share (2023) | 33.5% |
| Market Share (2033) | 31.8% |
| BPS Analysis | -169 |
| Country | China |
|---|---|
| Market Share (2023) | 6.7% |
| Market Share (2033) | 4.2% |
| BPS Analysis | -245 |
| Country | UK |
|---|---|
| Market Share (2023) | 6.4% |
| Market Share (2033) | 7.1% |
| BPS Analysis | 63 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.8% |
| Market Share (2033) | 7.6% |
| BPS Analysis | 177 |
| Country | Japan |
|---|---|
| Market Share (2023) | 4.8% |
| Market Share (2033) | 2.7% |
| BPS Analysis | -208 |
The USA dominates the globe with a total market share of about 33.1% in 2022, and is expected to continue to experience the same growth throughout the forecast period.
One of the key reasons fueling the market's growth throughout the forecast period is the rising number of patients choosing gene therapy to treat diseases like hemophilia, heart disease, diabetes, cystic fibrosis, cancer, and AIDS.
The increased development of gene therapy has increased the demand for plasmid DNA. Collaborations between businesses, various organizations, academic institutions, and nonprofit groups are growing as they work to create viral vectors and plasmid DNA. These elements encourage market expansion in the United States.
Germany held a market share of nearly 5.6% in the global viral vector development market in 2022.
In February 2020, the US production facility of the German-based viral vector company Vibalogics, CDMO was established.
By providing CDMO viral vector, this facility in Massachusetts that was developed with a USD 150 million investment, is anticipated to seize the North American market. With such expansions taking place among the key players into developing regions, the market is set to expand in Germany
China held a share of around 7.1% in the global market, in 2022.
In order to increase its capabilities and production capacity, VectorBuilder stated in April 2022 that it would build a USD 500 million gene delivery and research facility in Guangzhou, China.
The "Gene Delivery Research and Manufacturing Campus," as it has been dubbed by contract development manufacturing organization (CDMO) VectorBuilder, which offers gene delivery systems, will be constructed over the course of four years.
The campus will have 30 production suites, according to the company, that can produce plasmids, cell lines, adeno-associated virus (AAV), lentivirus, messenger RNA (mRNA), and other viral and non-viral vectors.
Such advancements within the country are expected to propel the growth of the overall market throughout the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Adeno-associated viral vectors are set to hold a share of around 37.0% in the global market, in 2023.
Adeno-associated viral vectors are the most efficient way to transfer genes to treat a wide range of human illnesses. Recent advancements in the design of therapeutically appealing AAV capsids, genome optimization, and the use of advanced biotechnologies have resulted in a considerable expansion of the area of gene therapy.
Two AAV-based drugs have been approved by regulators in the US or Europe, proving the clinical and preclinical efficacy of AAV as the ideal therapeutic vector for gene editing, gene silencing, and gene substitution.
The stable expression system will hold a global market share of around 85.80% in 2023.
Owing of its intricacy, viral vector manufacturing is still evolving. The majority of researchers acknowledge that obtaining sufficient yields of functional capsids with the required genetic payload represents the biggest challenge.
The most commonly used strategy is transient transfection, which effectively creates a cell line for every production cycle or a "cell factory" for a single production cycle. A stable and optimised manufacturing cell line, analogous to the ones used for other biologics, would provide a more reliable approach and be scalable if cells were cultured in suspension.
Over the anticipated years, this is expected to increase the segment value.
Gene therapy applications are set to hold a market share of around 55.1% in the global market in 2023.
Because viruses have proven to be particularly effective at entering cells, vectors are frequently created from them. All viral genes are removed from vectors before they are changed to solely carry therapeutic genes, making them safe to employ.
Three different types of vectors—adeno-associated virus (AAV) vectors, adenovirus vectors, or lentivirus vectors—are used by almost all gene therapies currently on the market.
Viral vectors are used in gene therapy to address more than just symptoms. With the genetic information they contain, vectors can modify a cell's behavior and target the underlying cause of a disease.
They are frequently used for uncommon genetic disorders for whom there are few to no other effective treatments, and they normally only need to be delivered once.
Academic and Research Institutes are set to hold a significant market share of around 45.7% globally, in 2023.
According to data provided by the WHO and FDA, by February 2022, there were 114 candidate vaccines in clinical trials, 75 animal preclinical trials, and 14 vaccinations that have been licensed for emergency use.
In order to develop drug candidates more efficiently, with enhanced therapeutic potential and greater access for patients worldwide, there has been a surge in collaborations between pharmaceutical companies and academic and research institutes, thus propelling segment growth within the overall market.
The market for the production of plasmid DNA and viral vector CDMO has become extremely competitive in recent years as a result of the introduction of numerous companies in these industries.
The main tactic used by the leading firms to stay ahead of their rivals is the expansion of production facilities. A cost-effective strategy for the rapid expansion and capacity building for viral vector process development for the manufacturers is the acquisition of small regional companies.
Recent Market Developments
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the viral vector development market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Virus, Application, Expression System, End User, and Region |
| Key Companies Covered | Thermo Fisher Scientific Inc; Charles River (Cobra Biologics); NOVASEP; uniQure N.V; Waisman Biomanufacturing; Creative Biogene; GenScript Biotech Corporation; Novartis AG; Merck KGaA; Takara Bio, Inc.; FUJIFILM Diosynth Biotechnologies; LONZA; Danaher Corp. (Aldevron); Sirion Biotech GmbH; AGC Biologics |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The viral vector development market is pegged at a value of USD 730.7 million in 2023.
The viral vector development market is estimated to reach USD 4.1 billion by 2033.
Sales of viral vector development are anticipated to surge at a noteworthy CAGR of 18.7% through 2033.
The United States has turned into a key hub in the market with a sizeable share of 33.1% in 2022.
The viral vector development market reached a value of USD 624.7 million In 2022.
1. Executive Summary | Viral Vector Development Market 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Virus 7.1. Lentiviral Vectors 7.2. Adenoviral Vectors 7.3. Adeno-Associated Viral Vectors 7.4. Retrovirus 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Expression System 8.1. Transient 8.2. Stable 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 9.1. Gene Therapy 9.2. Vaccines 9.3. Cancer Therapy 9.4. Others 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 10.1. Biotechnology Companies 10.2. Pharmaceutical Companies 10.3. Contract Research Organization (CRO) 10.4. Academic and Research Institutes 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa (MEA) 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. Thermo Fisher Scientific Inc 20.2. Charles River (Cobra Biologics) 20.3. NOVASEP 20.4. uniQure N.V 20.5. Waisman Biomanufacturing 20.6. Creative Biogene 20.7. GenScript Biotech Corporation 20.8. Novartis AG 20.9. Merck KGaA 20.10. Takara Bio, Inc. 20.11. FUJIFILM Diosynth Biotechnologies 20.12. LONZA 20.13. Danaher Corp. (Aldevron) 20.14. Sirion Biotech GmbH 20.15. AGC Biologics 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Viral Vector Development Market
